Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765321000098/mck-20210930.htm
August 2023
July 2023
June 2023
June 2023
May 2023
April 2023
February 2023
February 2023
November 2022
November 2022
Second-Quarter | Year-to-Date | |||||||||||||||||||||||||||||||||||||
($ in millions, except per share amounts) | FY22 | FY21 | Change | FY22 | FY21 | Change | ||||||||||||||||||||||||||||||||
Revenues | $ | 66,576 | $ | 60,808 | 9 | % | $ | 129,250 | $ | 116,487 | 11 | % | ||||||||||||||||||||||||||
Income from Continuing Operations 1 | 267 | 577 | (54) | 756 | 1,022 | (26) | ||||||||||||||||||||||||||||||||
Adjusted Earnings 1,2 | 958 | 784 | 22 | 1,838 | 1,237 | 49 | ||||||||||||||||||||||||||||||||
Earnings per Diluted Share 1 | 1.71 | 3.54 | (52) | 4.82 | 6.26 | (23) | ||||||||||||||||||||||||||||||||
Adjusted Earnings per Diluted Share 1,2 | 6.15 | 4.80 | 28 | 11.71 | 7.58 | 54 | ||||||||||||||||||||||||||||||||
1 Reflects continuing operations attributable to McKesson, net of tax 2 Represents a non-GAAP financial measure; refer to the reconciliations of non-GAAP financial measures included in accompanying schedules |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/927653/000092765321000098/mck-20210930.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Mckesson Corp.
Mckesson Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
However, other risks, expenses, and future developments, such as additional government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods, including our McKesson Canada reporting unit within our International segment and our RxCrossroads reporting unit within our RxTS segment, where the risk of a material goodwill impairment is higher than other reporting units.
The Company utilized the net proceeds from this note for general corporate purposes; We returned $1.4 billion of cash to shareholders during the six months ended September 30, 2021 through $1.3 billion of share repurchases under an accelerated share repurchase ("ASR") program entered into in May 2021, and $134 million of dividend payments.
Material changes to key assumptions and estimates can decrease the projected cash flows or increase the discount rates and have resulted in impairment charges of certain long-lived assets and could potentially result in future impairment charges.
Six Months Ended September 30, 2021 vs. 2020 Operating profit increased for this segment for the six months ended September 30, 2021 compared to the same prior year period primarily due to the contribution from our COVID-19 vaccine distribution program, growth in specialty pharmaceuticals, favorability from the prior year OSA charge described above, net cash proceeds received of $46 million representing our share of antitrust legal settlements, and the recovery of prescription volumes from the prior year impact of COVID-19.
During the six months ended September 30, 2020, particularly during the first quarter, we had lower pharmaceutical volumes, specialty drug volumes, and patient care visits that negatively impacted our consolidated revenues and income from continuing operations before income taxes.
U.S. Pharmaceutical Three Months Ended...Read more
The increase in revenues is...Read more
55 MD&A Index FINANCIAL REVIEW...Read more
For the six months ended...Read more
Medical-Surgical Solutions Three Months Ended...Read more
Six Months Ended September 30,...Read more
Corporate Expenses, Net Corporate expenses,...Read more
Operating activities for the six...Read more
50 MD&A Index FINANCIAL REVIEW...Read more
Corporate expenses, net also includes...Read more
Medical-Surgical Solutions Three Months Ended...Read more
Six Months Ended September 30,...Read more
Our debt to capital ratio...Read more
Our unfavorable return on equity...Read more
Revenues for this segment were...Read more
Refer to the "Restructuring Initiatives...Read more
Interest Expense Interest expense decreased...Read more
Consolidated working capital decreased at...Read more
New Accounting Pronouncements New accounting...Read more
We also had favorable contributions...Read more
Operating activities for the six...Read more
The exact amount that would...Read more
Our debt to capital ratio...Read more
Because of the many uncertainties...Read more
Changes to any of the...Read more
Prescription Technology Solutions Three Months...Read more
Refer to the "Trends and...Read more
47 MD&A Index FINANCIAL REVIEW...Read more
Operating loss for the three...Read more
Revenues for this segment were...Read more
Revenues for this segment were...Read more
This amount excludes the proportionate...Read more
The State of New York...Read more
Under the Domination Agreement, the...Read more
As previously disclosed in our...Read more
The various responses we put...Read more
During the first half of...Read more
However, there can be no...Read more
Fluctuations in our reported income...Read more
The recovery of prescription volume...Read more
This was partially offset by...Read more
We have not observed a...Read more
For the six months ended...Read more
Overall, during 2022 we have...Read more
52 MD&A Index FINANCIAL REVIEW...Read more
Six Months Ended September 30,...Read more
In future periods, fair value...Read more
During the three months ended...Read more
During the three months ended...Read more
Six Months Ended September 30,...Read more
Market growth was partially offset...Read more
This was also partially offset...Read more
We believe that a broad...Read more
We believe that our future...Read more
This was partially offset by...Read more
Under the proposed agreement, the...Read more
bp - basis points Revenues...Read more
We believe that we have...Read more
Refer to Item 1A -...Read more
At March 31, 2021, the...Read more
At September 30, 2021, we...Read more
LIFO credits are lower in...Read more
53 MD&A Index FINANCIAL REVIEW...Read more
Restructuring Initiatives and Long-Lived Asset...Read more
International Three Months Ended September...Read more
Market growth was partially offset...Read more
Consistent with the terms of...Read more
During the first quarter of...Read more
Gross profit for the six...Read more
Impact to our Results of...Read more
Subsequently, during the first half...Read more
Overall, these COVID-19 related items...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Mckesson Corp provided additional information to their SEC Filing as exhibits
Ticker: MCK
CIK: 927653
Form Type: 10-Q Quarterly Report
Accession Number: 0000927653-21-000098
Submitted to the SEC: Mon Nov 01 2021 5:41:12 PM EST
Accepted by the SEC: Tue Nov 02 2021
Period: Thursday, September 30, 2021
Industry: Wholesale Drugs Proprietaries And Druggists Sundries